查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1420987

抗癌药物市场（药物类型：细胞毒性药物、标靶药物和荷尔蒙药物；治疗类型：化疗、标靶治疗、免疫治疗等）- 2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Anticancer Drugs Market (Drug Type: Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs; and Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 226 Pages | 商品交期: 2-10个工作天内

价格

抗癌药物市场 - 报告范围

TMR 关于全球抗癌药物市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球抗癌药物市场的收入2017-2031年期间，考虑2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球抗癌药物市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解抗癌药物市场。

市场概况
2023年市场价值 1,402 亿美元
2031 年市场价值 3031 亿美元
CAGR 9.1%

该报告深入探讨了全球抗癌药物市场的竞争格局。全球抗癌药物市场的主要参与者已被确定，并且每个参与者都已根据各种属性进行了分析。公司概况、财务状况、近期发展和 SWOT 是本报告中介绍的全球抗癌药物市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2023-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按药物类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药物类型，2023-2031
    • 细胞毒性药物
      • 烷基化剂
      • 抗代谢药
      • 其他的
    • 标靶药物
      • 单株抗体
      • 酪胺酸激酶抑制剂
      • 其他的
    • 荷尔蒙药物
  • 市场吸引力分析：按药品类型

第 7 章：全球市场分析与预测：按治疗类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2023-2031
    • 化疗
    • 标靶治疗
    • 免疫疗法
    • 其他的
  • 市场吸引力分析：按治疗类型

第 8 章：全球市场分析与预测：按癌症类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依癌症类型，2023-2031
    • 肺癌
    • 乳癌
    • 白血病
    • 大肠直肠癌
    • 其他的
  • 市场吸引力分析：按治疗类型

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2023-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Novartis AG
    • Pfizer Inc
    • Bayer AG
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc
    • CELGENE CORPORATION
    • Amgen Inc
Product Code: TMRGL12458

Anticancer Drugs Market - Scope of Report

TMR's report on the global anticancer drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anticancer drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticancer drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anticancer drugs market.

Market Snapshot
Market Value in 2023US$ 140.2 Bn
Market Value in 2031US$ 303.1 Bn
CAGR9.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anticancer drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anticancer drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anticancer drugs market.

The report delves into the competitive landscape of the global anticancer drugs market. Key players operating in the global anticancer drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anticancer drugs market profiled in this report.

Key Questions Answered in Global anticancer drugs Market Report:

  • What is the sales/revenue generated by anticancer drugs across all regions during the forecast period?
  • What are the opportunities in the global anticancer drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Anticancer Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global anticancer drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anticancer drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anticancer drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticancer Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anticancer Drugs Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Anticancer Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2023-2031
    • 6.3.1. Cytotoxic Drugs
      • 6.3.1.1. Alkylating Agents
      • 6.3.1.2. Antimetabolites
      • 6.3.1.3. Others
    • 6.3.2. Targeted Drugs
      • 6.3.2.1. Monoclonal Antibodies
      • 6.3.2.2. Tyrosine Kinase Inhibitors
      • 6.3.2.3. Others
    • 6.3.3. Hormonal Drugs
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Anticancer Drugs Market Analysis and Forecast, by Therapy Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Therapy Type, 2023-2031
    • 7.3.1. Chemotherapy
    • 7.3.2. Targeted Therapy
    • 7.3.3. Immunotherapy
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Therapy Type

8. Global Anticancer Drugs Market Analysis and Forecast, by Cancer Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Cancer Type, 2023-2031
    • 8.3.1. Lung Cancer
    • 8.3.2. Breast Cancer
    • 8.3.3. Leukemia
    • 8.3.4. Colorectal Cancer
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Therapy Type

9. Global Anticancer Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2023-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Anticancer Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2023-2031
    • 10.3.1. Cytotoxic Drugs
      • 10.3.1.1. Alkylating Agents
      • 10.3.1.2. Antimetabolites
      • 10.3.1.3. Others
    • 10.3.2. Targeted Drugs
      • 10.3.2.1. Monoclonal Antibodies
      • 10.3.2.2. Tyrosine Kinase Inhibitors
      • 10.3.2.3. Others
    • 10.3.3. Hormonal Drugs
  • 10.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 10.4.1. Chemotherapy
    • 10.4.2. Targeted Therapy
    • 10.4.3. Immunotherapy
    • 10.4.4. Others
  • 10.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 10.5.1. Lung Cancer
    • 10.5.2. Breast Cancer
    • 10.5.3. Leukemia
    • 10.5.4. Colorectal Cancer
    • 10.5.5. Others
  • 10.6. Market Value Forecast, by Country, 2023-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Type
    • 10.7.2. By Therapy Type
    • 10.7.3. By Cancer Type
    • 10.7.4. By Country

11. Europe Anticancer Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2023-2031
    • 11.3.1. Cytotoxic Drugs
      • 11.3.1.1. Alkylating Agents
      • 11.3.1.2. Antimetabolites
      • 11.3.1.3. Others
    • 11.3.2. Targeted Drugs
      • 11.3.2.1. Monoclonal Antibodies
      • 11.3.2.2. Tyrosine Kinase Inhibitors
      • 11.3.2.3. Others
    • 11.3.3. Hormonal Drugs
  • 11.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 11.4.1. Chemotherapy
    • 11.4.2. Targeted Therapy
    • 11.4.3. Immunotherapy
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 11.5.1. Lung Cancer
    • 11.5.2. Breast Cancer
    • 11.5.3. Leukemia
    • 11.5.4. Colorectal Cancer
    • 11.5.5. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Therapy Type
    • 11.7.3. By Cancer Type
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Anticancer Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2023-2031
    • 12.3.1. Cytotoxic Drugs
      • 12.3.1.1. Alkylating Agents
      • 12.3.1.2. Antimetabolites
      • 12.3.1.3. Others
    • 12.3.2. Targeted Drugs
      • 12.3.2.1. Monoclonal Antibodies
      • 12.3.2.2. Tyrosine Kinase Inhibitors
      • 12.3.2.3. Others
    • 12.3.3. Hormonal Drugs
  • 12.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 12.4.1. Chemotherapy
    • 12.4.2. Targeted Therapy
    • 12.4.3. Immunotherapy
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 12.5.1. Lung Cancer
    • 12.5.2. Breast Cancer
    • 12.5.3. Leukemia
    • 12.5.4. Colorectal Cancer
    • 12.5.5. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Therapy Type
    • 12.7.3. By Cancer Type
    • 12.7.4. By Country/Sub-region

13. Latin America Anticancer Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2023-2031
    • 13.3.1. Cytotoxic Drugs
      • 13.3.1.1. Alkylating Agents
      • 13.3.1.2. Antimetabolites
      • 13.3.1.3. Others
    • 13.3.2. Targeted Drugs
      • 13.3.2.1. Monoclonal Antibodies
      • 13.3.2.2. Tyrosine Kinase Inhibitors
      • 13.3.2.3. Others
    • 13.3.3. Hormonal Drugs
  • 13.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 13.4.1. Chemotherapy
    • 13.4.2. Targeted Therapy
    • 13.4.3. Immunotherapy
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 13.5.1. Lung Cancer
    • 13.5.2. Breast Cancer
    • 13.5.3. Leukemia
    • 13.5.4. Colorectal Cancer
    • 13.5.5. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Therapy Type
    • 13.7.3. By Cancer Type
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Anticancer Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Type, 2023-2031
    • 14.3.1. Cytotoxic Drugs
      • 14.3.1.1. Alkylating Agents
      • 14.3.1.2. Antimetabolites
      • 14.3.1.3. Others
    • 14.3.2. Targeted Drugs
      • 14.3.2.1. Monoclonal Antibodies
      • 14.3.2.2. Tyrosine Kinase Inhibitors
      • 14.3.2.3. Others
    • 14.3.3. Hormonal Drugs
  • 14.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 14.4.1. Chemotherapy
    • 14.4.2. Targeted Therapy
    • 14.4.3. Immunotherapy
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 14.5.1. Lung Cancer
    • 14.5.2. Breast Cancer
    • 14.5.3. Leukemia
    • 14.5.4. Colorectal Cancer
    • 14.5.5. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Therapy Type
    • 14.7.3. By Cancer Type
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. F. Hoffmann-La Roche Ltd
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Eli Lilly and Company
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Pfizer Inc
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Bayer AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AstraZeneca
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Takeda Pharmaceutical Company Limited
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Merck & Co., Inc
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. CELGENE CORPORATION
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Amgen Inc
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 02: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 03: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 04: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2023-2031
  • Table 05: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country, 2023-2031
  • Table 06: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 07: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 08: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 09: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 11: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 12: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 13: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 15: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 16: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 17: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 19: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 20: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 21: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 23: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 24: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031

List of Figures

  • Figure 01: Global Anticancer Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
  • Figure 02: Global Anticancer Drugs Market Revenue (US$ Mn), by Drug Type, 2022
  • Figure 03: Global Anticancer Drugs Market Value Share, by Drug Type, 2022
  • Figure 04: Global Anticancer Drugs Market Revenue (US$ Mn), by Therapy Type, 2022
  • Figure 05: Global Anticancer Drugs Market Value Share, by Therapy Type, 2022
  • Figure 06: Global Anticancer Drugs Market Revenue (US$ Mn), by Cancer Type, 2022
  • Figure 07: Global Anticancer Drugs Market Value Share, by Cancer Type, 2022
  • Figure 08: Global Anticancer Drugs Market Value Share, by Region, 2022
  • Figure 09: Global Anticancer Drugs Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 11: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 12: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 13: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 14: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 15: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 16: Global Anticancer Drugs Market Value Share Analysis, by Region, 2023 and 2031
  • Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 19: North America Anticancer Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Anticancer Drugs Market Value Share Analysis, by Country, 2023 and 2031
  • Figure 21: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 22: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 23: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 24: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 25: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 26:North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 27: Europe Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 28: Europe Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 30: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 31: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 32: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 33: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 34: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 35: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 36: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 37: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 39: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 40: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 41: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 42: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 43: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 44: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 45: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 46: Latin America Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 48: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 49: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 50: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 51: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 52: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 53: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 54: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 55: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 57: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 58: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 59: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 60: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 61: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 62: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031